Claims
- 1. An imidazole derivative of the formula ##STR5## wherein AR.sub.1 and AR.sub.2 each independently is phenyl, or phenyl substituted by halogen, C.sub.1-4 -alkyl, or C.sub.1-4 -alkoxy,
- R.sub.1 is pyrrolyl, indolyl, or imidazolyl, or one of these groups substituted by C.sub.1-6 -alkyl, carboxy, carboxy-C.sub.1-4 -alkyl, benzyl, or benzenesulfonyl, wherein any carboxy group can be esterified by a C.sub.1-6 -alkyl moiety, and wherein the point of attachment of the R.sub.1 group to the imidazole ring is a C-atom; and
- R.sub.2 is methylene, dimethylene, trimethylene, or tetramethylene linked to the nitrogen atom of R.sub.1,
- or a physiologically acceptable salt thereof with an acid, or, when R.sub.1 is substituted by carboxy, a physiologically acceptable salt thereof with a base.
- 2. An imidazole derivative of claim 1, wherein AR.sub.1 and AR.sub.2 each is phenyl or phenyl substituted in the para-position by fluorine, chlorine or an alkoxy group of 1-4 carbon atoms.
- 3. An imidazole derivative of claim 2, wherein AR.sub.1 and AR.sub.2 each is phenyl, 4-fluorophenyl, 4-chlorophenyl, or 4-methoxyphenyl.
- 4. An imidazole derivative of claim 1, wherein R.sub.1 is 2-pyrrolyl, 3-pyrrolyl, 2-indolyl or, 2-imidazolyl, or one of the foregoing substituted by methyl or lower alkoxycarbonyl groups.
- 5. 2,3-Bis(4-methoxyphenyl)-5,6-dihydroimidazo-[1,2-a]pyrrolo[2,1-c]pyrazine, a compound of claim 1.
- 6. 2,3-Bis(4-methoxyphenyl)-6,7-dihydro-5H-imidazo[1,2-a]pyrrolo[2,1-c]-1,4-diazepine, a compound of claim 1.
- 7. 2,3-Bis(4-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrrolo[2,1-c]-1,4-diazocine, a compound of claim 1.
- 8. A pharmaceutical composition comprising an antiinflammtorily effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 9. A pharmaceutical composition comprising 1-250 mg of a compound of claim 1 and 50 mg to 2 g of a pharmaceutically acceptable carrier.
- 10. A method of treating inflammation in a patient in need of such treatment comprising administering an amount of a compound of claim 1 effective for such treatment.
- 11. A method of treating an allergic disease in a patient in need of such treatment comprising administering an amount of a compound of claim 1 effective for such treatment.
- 12. A method of treating a migraine in a patient in need of such treatment comprising administering an amount of a compound of claim 1 effective for such treatment.
- 13. A method of treating dysmenorrhea in a patient in need of such treatment comprising administering an amount of a compound of claim 1 effective for such treatment.
- 14. A method of treating an allergic disease in a patient in need of such treatment comprising administering an effective amount of a compound of the formula ##STR6## wherein AR.sub.1 and AR.sub.2 each independently is phenyl, or phenyl substituted by halogen, C.sub.1-4 -alkyl, or C.sub.1-4 -alkoxy,
- R.sub.1 is thiazolyl or thiazolyl substituted by C.sub.1-6 -alkyl, carboxy, carboxy-C.sub.1-4 -alkyl, benzyl, or benzenesulfonyl, wherein any carboxy group can be esterified by a C.sub.1-6 -alkyl moiety, and wherein the point of attachment of the R.sub.1 group to the imidazole ring is a C-atom; and
- R.sub.2 is hydrogen, C.sub.1-6 -alkyl, or halo-C.sub.1-6 -alkyl or is methylene, dimethylene, trimethylene, or tetramethylene linked to the nitrogen atom of R.sub.1,
- or a physiologically acceptable salt thereof with an acid, or, when R.sub.1 is substituted by carboxy, a physiologically acceptable salt thereof with a base.
- 15. A method of treating a migraine in a patient in need of such treatment comprising administering an effective amount of a compound of the formula ##STR7## AR.sub.1 and AR.sub.2 each independently is phenyl, or phenyl substituted by halogen, C.sub.1-4 -alkyl, or C.sub.1-4 -alkoxy,
- R.sub.1 is thiazolyl or thiazolyl substituted by C.sub.1-6 -alkyl, carboxy, carboxy-C.sub.1-4 -alkyl, benzyl, or benzenesulfonyl, wherein any carboxy group can be esterified by a C.sub.1-6 -alkyl moiety, and wherein the point of attachment of the R.sub.1 group to the imidazole ring is a C-atom; and
- R.sub.2 is hydrogen, C.sub.1-6 -alkyl, or halo-C.sub.1-6 -alkyl or is methylene, dimethylene, trimethylene, or tetramethylene linked to the nitrogen atom of R.sub.1,
- or a physiologically acceptable salt thereof with an acid, or, when R.sub.1 is substituted by carboxy, a physiologically acceptable salt thereof with a base.
- 16. A method of treating dysmenorrhea in a patient in need of such treatment comprising administering an effective amount of a compound of the formula ##STR8## AR.sub.1 and AR.sub.2 each independently is phenyl, or phenyl substituted by halogen, C.sub.1-4 -alkyl, or C.sub.1-4 -alkoxy,
- R.sub.1 is thiazolyl or thiazolyl substituted by C.sub.1-6 -alkyl, carboxy, carboxy-C.sub.1-4 -alkyl, benzyl, or benzenesulfonyl, wherein any carboxy group can be esterified by a C.sub.1-6 -alkyl moiety, and wherein the point of attachment of the R.sub.1 group to the imidazole ring is a C-atom; and
- R.sub.2 is hydrogen, C.sub.1-6 -alkyl, or halo-C.sub.1-6 -alkyl or is methylene, dimethylene, trimethylene, or tetramethylene linked to the nitrogen atom of R.sub.1,
- or a physiologically acceptable salt thereof with an acid, or, when R.sub.1 is substituted by carboxy, a physiologically acceptable salt thereof with a base.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3141063 |
Oct 1981 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 434,036, filed Oct. 13, 1982, now U.S. Pat. No. 4,466,976.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3707475 |
Lombardino |
Dec 1972 |
|
4402960 |
Niedballa et al. |
Sep 1983 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
434036 |
Oct 1982 |
|